(Z)-N’-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide | 939999-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (Z)-N’-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide
• 英文别名: (Z)-N'-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide；N'-hydroxy-2-oxo-1H-pyridine-4-carboximidamide
• CAS: 939999-66-3
• 化学式: C₆H₇N₃O₂
• 分子量: 153.14
• InChiKey: ZXWRDKLWYHKIHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (Z)-N’-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide 在 盐酸 、 potassium tert-butylate 、 溶剂黄146 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 7.0h， 生成 3-(2-oxo-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)pyridin-1-(2H)-yl)-2-(3-(trifluoromethyl)phenyl)propanoic acid
  参考文献：
  名称：

  [EN] 3- HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
  [FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS PAR UN 3-HÉTÉROARYLE À TITRE D'INHIBITEURS D'HISTONE DÉSACÉTYLASE 6 (HDAC6)

  摘要：

  本发明涉及通式(I)的取代5-三氟甲基噁二唑化合物或其药用可接受的盐。具体而言，本发明涉及一类杂环取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、精神分裂症和中风等神经退行性疾病，以及其他疾病。

  公开号：

  WO2017222952A1
• 作为产物：
  描述：

  4-氰基-2(1H)-吡啶酮 在 羟胺 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 (Z)-N’-hydroxy-2-oxo-1,2-dihydropyridine-4-carboximidamide
  参考文献：
  名称：

  [EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS
  [FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)

  摘要：

  本发明涉及通式（I）的取代5-三氟甲基噁二唑化合物或其药学上可接受的盐。具体而言，本发明涉及一类芳基和杂环芳基取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。

  公开号：

  WO2017222951A1

文献信息

• [EN] SUBSTITUTED OXADIAZOLE COMPOUNDS AND THEIR USE AS S1P1 AGONISTS<br/>[FR] COMPOSÉS OXADIAZOLES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGONISTES DU S1P1
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012040532A1

  公开（公告）日：2012-03-29

  Disclosed are compounds of Formula (I): [PLEASE INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  公开了式(I)的化合物：[请在此处插入化学结构]或其立体异构体、N-氧化物、盐或前药；其中：环A是苯基或5至6元杂芳基；(i) R1和R2各自独立地是C1-C4烷基；或(ii) R1和R2与其所连接的碳原子一起形成一个环状基团；Q是带有零至3个取代基的苯基或5至6元杂芳基；并且R3、L1、L2和n如本文所定义。还公开了使用这些化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗、预防或减缓各种治疗领域中的疾病或障碍的进展方面有用，例如自身免疫性疾病和血管疾病。
• [EN] 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS<br/>[FR] 5-TRIFLUOROMÉTHYL-OXADIAZOLES SUBSTITUÉS EN 3-ARYLE ET HÉTÉROARYLE EN TANT QU'INHIBITEURS DE L'HISTONE DÉSACÉTYLASE 6 (HDAC6)
  申请人：MERCK SHARP & DOHME

  公开号：WO2017222951A1

  公开（公告）日：2017-12-28

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式（I）的取代5-三氟甲基噁二唑化合物或其药学上可接受的盐。具体而言，本发明涉及一类芳基和杂环芳基取代的通式I的5-三氟甲基噁二唑化合物，可能作为HDAC6抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。
• SUBSTITUTED OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130190361A1

  公开（公告）日：2013-07-25

  Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及以下式(I)的化合物或其立体异构体、N-氧化物、盐或前药： 其中：环A是苯基或5-至6-成员杂环基； (i) R1和R2独立地是C1-C4烷基；或 (ii)R1和R2与它们连接的碳原子一起形成一个环状基团； Q是苯基或5-至6-成员杂环基，其被0-3个取代基取代；R3、L1、L2和n的定义详见说明书。 本发明还涉及将这些化合物用作选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在多种治疗领域中用于治疗、预防或减缓疾病或障碍的进展，如自身免疫性疾病和血管疾病。
• Substituted oxadiazole compounds
  申请人：Das Jagabandhu

  公开号：US09187437B2

  公开（公告）日：2015-11-17

  Disclosed are compounds of Formula (I): or stereoisomers, N-oxides, salts, or prodrugs thereof; wherein: Ring A is phenyl or 5- to 6-membered heteroaryl; (i) R1 and R2 are independently C1-C4 alkyl; or (ii) R1 and R2 together with the carbon atom to which they are attached, form a cyclic group; Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents; and R3, L1, L2, and n are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及公式（I）的化合物：或其立体异构体，N-氧化物，盐或前药；其中：环A是苯基或5-至6-成员杂环基；（i）R1和R2独立地为C1-C4烷基；或（ii）R1和R2与它们所附着的碳原子一起形成一个环状基团；Q是苯基或5-至6-成员杂环基，其被零到3个取代基取代；R3，L1，L2和n在此定义。本发明还涉及使用这种化合物作为G蛋白偶联受体S1P1的选择性激动剂的方法，以及包含这种化合物的药物组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或障碍方面非常有用，例如自身免疫疾病和血管疾病。
• 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US11066396B2

  公开（公告）日：2021-07-20

  The present invention is directed to substituted 5-trifluoromethyl oxadiazole compounds of generic formula (I) or a pharmaceutically acceptable salt thereof. In particular, the invention is directed to a class of aryl and heteroaryl substituted 5-trifluoromethyl oxadiazole compounds of formula I which may be useful as HDAC6 inhibitors for treating cellular proliferative diseases, including cancer, neurodegenerative diseases, such as schizophrenia and stroke, as well as other diseases.

  本发明涉及通式(I)的取代的5-三氟甲基噁二唑化合物或其药学上可接受的盐。特别是，本发明涉及一类式 I 的芳基和杂芳基取代的 5-三氟甲基噁二唑化合物，其可作为 HDAC6 抑制剂用于治疗细胞增殖性疾病，包括癌症、神经退行性疾病（如精神分裂症和中风）以及其他疾病。